Frederick L. Locke, MD
Several studies presented at the 2018 ASCO Annual Meeting helped further refine and inform treatment strategies for the budding class of chimeric antigen receptor (CAR) T-cell therapies, with a focus on predicting adverse events (AEs) and optimizing efficacy.
This analysis showed that patients with Philadelphia chromosome (Ph)-like genetic characteristics were highly unlikely to experience grade 4 or 5 cytokine release syndrome (CRS) or neurotoxicity.
Durability of Response
With the rapid develop of the CAR T-cell therapies, the durability of response and impact on long-term outcomes remains a question of interest, particularly as it factors into a value equation. As data from the clinical trials matures, it is becoming clear that patients experiencing a CR at month 3 to 6 are likely to experience a long-term remission.
... to read the full story